Entheon Biomedical Corp. (ENBI.CN)
CAD 0.1
(-16.67%)
CAD 0.1
(-16.67%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 85.32 Thousand CAD | -44.83% |
| 2022 | 154.65 Thousand CAD | -83.33% |
| 2021 | 927.71 Thousand CAD | 27.4% |
| 2020 | 728.19 Thousand CAD | 2496.88% |
| 2019 | 28.04 Thousand CAD | -28.05% |
| 2018 | 38.97 Thousand CAD | -78.97% |
| 2017 | 185.28 Thousand CAD | 1052.77% |
| 2016 | 16.07 Thousand CAD | 3371.49% |
| 2015 | 463.00 CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 41.55 Thousand CAD | -18.55% |
| 2024 Q3 | 20.19 Thousand CAD | -51.41% |
| 2024 Q1 | 51.01 Thousand CAD | -40.22% |
| 2023 FY | 85.32 Thousand CAD | -44.83% |
| 2023 Q2 | 89.03 Thousand CAD | -40.93% |
| 2023 Q1 | 150.73 Thousand CAD | -2.53% |
| 2023 Q4 | 85.32 Thousand CAD | 105.25% |
| 2023 Q3 | 41.57 Thousand CAD | -53.31% |
| 2022 Q2 | 1.13 Million CAD | 17.52% |
| 2022 Q3 | 62.76 Thousand CAD | -94.49% |
| 2022 FY | 154.65 Thousand CAD | -83.33% |
| 2022 Q1 | 968.72 Thousand CAD | 4.42% |
| 2022 Q4 | 154.65 Thousand CAD | 146.4% |
| 2021 Q2 | 105.67 Thousand CAD | -38.4% |
| 2021 FY | 927.71 Thousand CAD | 27.4% |
| 2021 Q1 | 171.55 Thousand CAD | -76.44% |
| 2021 Q4 | 927.71 Thousand CAD | 135.55% |
| 2021 Q3 | 393.84 Thousand CAD | 272.7% |
| 2020 FY | 728.19 Thousand CAD | 2496.88% |
| 2020 Q4 | 728.19 Thousand CAD | 4646.09% |
| 2020 Q2 | 17.91 Thousand CAD | -36.11% |
| 2020 Q1 | 28.04 Thousand CAD | 607.21% |
| 2020 Q3 | 15.34 Thousand CAD | -14.36% |
| 2019 Q2 | 4046.00 CAD | -89.62% |
| 2019 FY | 28.04 Thousand CAD | -28.05% |
| 2019 Q4 | 3965.00 CAD | -64.99% |
| 2019 Q3 | 11.32 Thousand CAD | 179.93% |
| 2019 Q1 | 38.97 Thousand CAD | 835.7% |
| 2018 Q2 | 199.95 Thousand CAD | 7.92% |
| 2018 Q3 | 2885.00 CAD | -98.56% |
| 2018 Q4 | 4165.00 CAD | 44.37% |
| 2018 Q1 | 185.28 Thousand CAD | 0.0% |
| 2018 FY | 38.97 Thousand CAD | -78.97% |
| 2017 FY | 185.28 Thousand CAD | 1052.77% |
| 2016 FY | 16.07 Thousand CAD | 3371.49% |
| 2015 FY | 463.00 CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 2.71 Million CAD | 96.863% |
| Asep Medical Holdings Inc | 3.05 Million CAD | 97.204% |
| BetterLife Pharma Inc. | 8.02 Million CAD | 98.936% |
| BioVaxys Technology Corp. | 3.48 Million CAD | 97.552% |
| ChitogenX Inc. | 6.71 Million CAD | 98.729% |
| Rapid Dose Therapeutics Corp. | 5.04 Million CAD | 98.308% |
| Defence Therapeutics Inc. | 4.06 Million CAD | 97.899% |
| Gemina Laboratories Ltd. | 3.04 Million CAD | 97.195% |
| Glow Lifetech Corp. | 2.34 Million CAD | 96.363% |
| Lexston Life Sciences Corp. | 39.86 Thousand CAD | -114.016% |
| Pharmala Biotech Holdings Inc. | 1.02 Million CAD | 91.708% |
| Doseology Sciences Inc. | 82.49 Thousand CAD | -3.435% |
| MYND Life Sciences Inc. | 5.77 Million CAD | 98.522% |
| Nova Mentis Life Science Corp. | 841.66 Thousand CAD | 89.862% |
| PharmaTher Holdings Ltd. | 252.9 Thousand CAD | 66.261% |
| PreveCeutical Medical Inc. | 5.95 Million CAD | 98.568% |
| Telescope Innovations Corp. | 1.35 Million CAD | 93.684% |